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Human carcinoembryonic antigen (CEA) is the prototypic member of a family of
highly related cell surface glycoproteins that includes carcinoembryonic antigen-
related cell adhesion molecule 6 (CEACAM6) and others. CEACAM6 (formerly NCA),
which belongs to the immunoglobulin superfamily, is a cell adhesion protein of the
CEA family. It is normally expressed on the epithelial surfaces and on the surface of
myeloid cells (CD66c). CEACAM6 is a multi-functional glycoprotein that mediates
homotypic binding with other CEA family members and heterotypic binding with
integrin receptors. It functions by organizing tissue architecture and regulating dif-
ferent signal transduction, while aberrant expression leads to the development of
human malignancies. It was first discovered in proliferating cells of adenomas and
hyperplastic polyps in comparison to benign colonic tissue when overexpressed on
the surface of various cell types in model systems. CEACAM6 functions as a pan-
inhibitor of cell differentiation and cell polarization, and it also causes distortion of
tissue architecture. Moreover, overexpression of CEACAM6 modulates cancer pro-
gression through aberrant cell differentiation, anti-apoptosis, cell growth and resis-
tance to therapeutic agents. In addition, CEACAM6 overexpression in multiple
malignancies promotes cell invasion and metastasis, thereby representing an
acquired advantage of tumor cells directly responsible for an invasive phenotype.
This review focuses on the findings supporting the mechanisms of actions linking
the oncogenic potential of CEACAM6 to the onset of cancer progression and patho-
genesis, especially in breast cancer, and to validating CEACAM6 as a target to pave
the way towards the design of efficient therapeutic strategies against breast cancer.
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1 | INTRODUCTION
Human carcinoembryonic antigen (CEA) is part of a larger family of
related glycoproteins made up of 2 separate branches: the CEA cel-
lular adhesion molecules (CEACAM) and the pregnancy-specific gly-
coprotein (PSG) subgroup.1 In addition, cell adhesion molecules
(CAM) are predominantly transmembrane glycoproteins, involved in
intercellular binding of adjacent cells to each other or to the extra-
cellular matrix (ECM). They play a crucial role in a number of biologi-
cal processes, including homeostasis, embryogenesis and
development of neural tissue, inflammation, immune cell transmigra-
tion and immune response.2 Four major groups of CAM have been
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Received: 20 September 2017 | Revised: 31 October 2017 | Accepted: 1 November 2017
DOI: 10.1111/cas.13437
Cancer Science. 2017;1–10. wileyonlinelibrary.com/journal/cas | 1
described: the immunoglobulin (Ig) superfamily, integrins, selectins
and cadherins.3 The CEACAM are highly glycosylated transmem-
brane proteins of the Ig superfamily, located on chromosome
19q13.1-13.2, and were described in 1972 (Figure 1).4,5 They are
involved in modulate cellular processes, such as neovascularization,
shaping of tissue architecture, angiogenesis, T-cell proliferation and
cell–cell recognition, and regulation of insulin action, and have also
been described as bacterial and viral pathogen receptors, such as
Neisseria species, Escherichia coli and Salmonella.6 Moreover, CEA-
CAM play an important role in tumor-associated mechanisms.7 The
CEACAM family consists of membrane-linked glycoproteins
anchored to the cell surface either by glycophosphatidyl-inositol
(GPI) anchor or a transmembrane domain, as well as secretory glyco-
proteins.8 The GPI-anchored members include CEACAM7 (formerly
CGM2), CEACAM8 (formerly CGM6), CEACAM5 and CEACAM6
(formerly NCA).9 CEACAM1 (formerly BGP), CEACAM3 (formerly
CGM1), CEACAM4 (formerly CGM7), CEACAM19, CEACAM20 and
CEACAM21 are all attached to the cell membrane through trans-
membrane domains.2 CEACAMs manifest their function as an inter-
cellular adhesion molecule through GPI anchorage to the cell surface
or transmembrane domains.8
Most of the research has been directed at CEACAM1 due to the
homology identified in a number of mammals, making it more
accessible as an in vivo model,10 as well as towards CEACAM5, the
gastrointestinal oncofetal antigen first described in 1965.8 It is found
in most carcinomas of the respiratory and genitourinary systems, in
breast cancer, and in cancers of the gastrointestinal tract.11 In con-
trast, CEACAM6, also referred to as CD66c, is a multi-functional gly-
coprotein that mediates homotypic binding with other CEA family
members and heterotypic binding with integrin receptors.12 It func-
tions by organizing tissue architecture and regulation of signal trans-
duction, while aberrant expression leads to the development of
human malignancies.12 It was first discovered in proliferating cells of
adenomas and hyperplastic polyps in comparison to benign colonic
tissue.13 Overexpression of CEACAM6 modulates cancer progression
through aberrant cell differentiation, anti-apoptosis, cell growth and
resistance to therapeutic agents.14 CEACAM6 overexpression in mul-
tiple malignancies promotes cell invasion and metastasis, thereby
representing an acquired advantage of tumor cells directly responsi-
ble for an invasive phenotype.15 In vitro studies have shown that
antibodies directed against CEACAM6 on overexpressing cells inhib-
ited cell migration, invasion and adhesion.15
This article will serve as a comprehensive review highlighting the
role of CEACAM6 in various malignancies, identifying common and
unique pathways suspected of playing a central role in the malignant
process. Furthermore, targeting CEACAM6 with novel therapeutic
approaches provides an opportunity to treat several human malig-
nancies.
2 | CARCINOEMBRYONIC ANTIGEN/
CARCINOEMBRYONIC ANTIGEN-RELATED
CELL ADHESION MOLECULE FAMILY:
CHROMOSOMAL LOCATION, EXPRESSION
AND REGULATION
2.1 | Chromosomal location of carcinoembryonic
antigen/carcinoembryonic antigen-related cell
adhesion molecules
The human CEACAM gene family is composed of 29 genes/pseudo-
genes and gene-like sequences that are clustered in human chromo-
some 19 (q13.2.).16 This large gene family can be divided into the
CEA subgroup (n = 12, where 5 of them are pseudogenes), the PSG-
subgroup (n = l1) and the incomplete non-expressed CGM (CEA
gene family member) subgroup (n = 6).17,18 These genes were
arranged during evolution into 850-kb distal clusters and 250-kb
proximal clusters in relation to the centromere, separated by 700 kb
of genomic DNA containing a few unrelated genes.19 CEACAM4,
CEACAM7, CEACAM5, CEACAM6 and CEACAM3 are closely clus-
tered in the proximal cluster; CEACAM1, CEACAM8 and PSG/CGM
genes are clustered in the distal cluster.16
Gene amplification is an essential mechanism of insertional muta-
genesis, in addition to loss of control mechanisms, structural altera-
tions, chromosome translocations and oncogene activation. The
comparative genome hybridization analysis identified DNA copy num-
ber changes in all cancers.20 The region 19q13.2-13.32, spanning
F IGURE 1 The carcinoembryonic antigen-related cell adhesion
molecule (CEACAM) gene superfamily.79 The CEACAM
immunoglobulin-like domain superfamily is a large family of proteins
encoded by 12 independent genes and located on chromosome 19.
The Ig domain consists generally of one IgV-like N-domain (red),
except CEACAM 16, which has 2 N-domains and IgC-like domains
identified as (A and B) shown in (blue). The membrane-linked
glycoproteins are anchored to the cell surface either by
transmembrane domain (green zigzag lines), such as CEACAM5-8, or
anchored to the membrane by glycophosphatidyl-inositol anchor
(green arrowhead), including CEACAM1, 3, 4, 19, 20 and 21.
CEACAM16 is a secreted version with no membrane anchorage. The
CEACAM 19 and 20 cytoplasmic domain has immune-receptor
tyrosine-based activator (ITAM) motifs (blue circles). Heavily N-
Glycosylation sites in all family members are shown as black lollipops
on the extracellular domains
2 | RIZEQ ET AL.
3.25 MB, is amplified in hepatocellular carcinoma as well as being
amplified in other cancers such as follicular lymphoma (19q13), mantle
cell lymphoma (19q13), respiratory tract small cell lung cancer
(19q13.1), non-small cell lung cancer (19qcen-q13.3), hepatocellular
carcinoma (19q13.1), breast carcinoma (19q13.1-qter), and chon-
drosarcoma (19q13.2),21 whereas deletion of this locus occurs infre-
quently and was only observed in colon tumors.22 It is clear that the
precise characterization of chromosomal amplicon areas will be of
prognostic and therapeutic value to revolutionize clinical molecular
genetics in oncology.
2.2 | Transcriptional regulation of carcinoembryonic
antigen/carcinoembryonic antigen-related cell
adhesion molecule 6
Studies on transcriptional regulation of the CEACAM family genes
have previously been performed with human CEACAMl and CEA-
CAM6 genes.23 Research on the regulation of other CEACAM family
genes in humans and other species is still scarce. The upstream pro-
moter sequences of CEACAM1 and CEACAM6 genes lack the classi-
cal TATA and CCAAT boxes. TATNCCAAT-less genes can generally
be grouped into: (i) constitutively active house-keeping genes with
relatively G/C-rich promoter regions, SPI sites and often multiple
transcriptional start sites; or (ii) genes lacking G/C-rich regions that
have tightly clustered transcriptional start sites that are differentially
or developmental regulated.24 However, in contrast to other
TATNCCAAT-less genes, CEACAM family genes possess features
from both groups.23 They have G/C-rich promoter regions and SPI
sites, but they also have clusters of transcriptional start sites and are
differentially expressed. CEACAM6 promoters show a sequence
homology of 80% within the first 230 nucleotides upstream of the
translational start site, where they could share the same transcrip-
tional binding factors. The sequences farther upstream diverge sig-
nificantly from each other.25
In TGF-b signaling, CEACAM6 was defined as a major
SMAD3-mediated target gene. Moreover, HER2 expression was
associated significantly with SMAD3 phosphorylation in only CEA-
CAM6-positive cancers.26 TGF-b elaborated in the malignant
tumor microenvironment (TME) binds to the type II receptor
(T_RII), promoting hetero-tetramerization with the type I receptor
(T_RI) and increasing the phosphorylation of SMAD3 by activated
T_RI. Phosphorylated SMAD3 forms a complex with Co-Smad
(SD4), which promotes translocation into the nucleus and activate
expression of target genes, specifically CEACAM6.27 Hence, HER2
signaling through the TGF-b pathway may regulate CEACAM6
expression.
Although genetics is concerned with gene expression as a func-
tion of DNA sequence, epigenetic alteration of gene expression can
be stably modulated by different mechanisms. It has been reported
that HDAC inhibitor (NaB) and DNA methyltransferase inhibitor (5-
AZA) upregulate CEA expression in different cancer cells.28 In colon
carcinoma cells, NaB and 5-AZA appear to have major effects in
increasing the rate of transcription through epigenetic modifications
of chromatin and DNA methylation, respectively.28 Furthermore, epi-
genetic analysis of CEACAM6 promoter in different primary breast
cancers, identified downregulation of expression level by hyperme-
thylation of CEACAM6 promoter among triple-negative breast can-
cers specifically.29 Strongly suggesting that aberrant DNA
hypermethylation of CEACAM6 promoter by overexpression of
DNMT3b, DNA methyltransferase enzymes, and concurrent methyla-
tion-dependent silencing might trigger breast cancer progression.
2.3 | Expression of carcinoembryonic antigen/
carcinoembryonic antigen-related cell adhesion
molecule 6
Each CEACAM family member has a distinct tissue-specific expres-
sion pattern that varies during different stages of development. In
healthy human adults, the expression of CEA is mostly found in
columnar epithelial cells and mucus-secreting cells of the colon.30
CEA can also be found at a lower level in secretory epithelial cells
present in the stomach and small intestine, in epithelial cells of the
prostate, in secretory epithelial and duct cells of the sweat glands, in
transitional epithelial cells of the urinary bladder, as well as in squa-
mous epithelial cells of the esophagus, tongue and cervix.13 Expres-
sion of CEA in lung, breast and pancreas is still controversial. The
expression pattern of CEACAM6 is somewhat broader but generally
similar to that of CEA with a few exceptions.30 CEACAM6 is not
expressed in small intestine, but in duct cells of the breast and pan-
creas, in myeloid cells of the bone marrow and spleen, and in pneu-
mocytes and bronchiole epithelial cells of the lung, as well as in
many other tissues.13 Over the past 10 years, a tremendous amount
of information regarding the expression patterns and potential of
CEACAM6 to serve as a prognostic indicator as well as a therapeutic
target has emerged.
3 | STRUCTURE OF CARCINOEMBRYONIC
ANTIGEN/CARCINOEMBRYONIC ANTIGEN-
RELATED CELL ADHESION MOLECULE 6
The ECM domains of CEACAM6 consist of an Ig variable-like N-
terminal domain followed by 6 (AIB l, A2B2, A3B3), 3 (AIB l, A2) or
2 (AlB1) C2-type Ig domains, respectively, as shown in Figure 2.31
CEACAM6 and CEACAM1 share striking homology at both the
nucleotide and amino acid levels. Relative to the CEA family, CEA-
CAM1 and CEACAM6 are 80/90% homologous, respectively, at the
nucleotide level and 70/85% homologous, respectively, at the amino
acid level.31 While CEACAM6 molecules are bound to the plasma
membrane by GPI anchors, CEACAM1 contains a transmembrane
domain followed by a cytoplasmic tail.32 This distinctive structural
feature may explain the opposite roles in human cancer of CEA-
CAM1 vs CEACAM6.
As mentioned above, CEACAM6 is bound to the plasma mem-
brane through a GPI anchor. Such anchors are synthesized in the
endoplasmic reticulum.33 The eukaryotic GPI anchor consists of a
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backbone of N-acetyl-glucosamine, 3 mannose residues, and ethano-
lamine bound to a phosphoinositol molecule covalently linked to a
glycerolipid moiety located within the outer leaflet of the plasma
membrane. CEACAM6 are likely attached to the GPI anchor through
an amide linkage between their C-terminus and the core phospho-
ethanolamine moiety of the anchor. There are variations of the core
structure of the eukaryotic GPI anchor, such as palmitoylation of the
inositol ring, number and length of lipid chains attached to glycerol,
and modifications of mannose residues.34 GPI-anchored proteins,
such as CEA and CEACAM6, are excluded from the polarized epithe-
lial cells and are only specifically targeted to apical membranes.35
Moreover, GPI-anchored proteins are found in specific rafts or
micro-domains of the plasma membrane known as detergent insol-
uble glycolipid domains (DIG).36 Several members of the Src-family
of GTP-binding proteins and protein tyrosine kinases involved in sig-
nal transduction pathways are often associated with the cytoplasmic
side of DIG.36
4 | FUNCTIONS OF CARCINOEMBRYONIC
ANTIGEN/CARCINOEMBRYONIC ANTIGEN-
RELATED CELL ADHESION MOLECULE 6
Carcinoembryonic antigen is expressed on the apical surface of
columnar epithelial cells and mucus-secreting goblet cells of the
human gastrointestinal tract, mainly in the upper one-third of the
colonic crypts. In addition, CEA is expressed in squamous epithelial
cells of the cervix and tongue,13 in sweat glands37 and in epithelial
cells of the prostate.38 CEACAM6 is expressed in epithelial cells of
the colon,39 lung and stomach, and in granulocytes and monocytes
as well.40
4.1 | Physiological functions of carcinoembryonic
antigen/carcinoembryonic antigen-related cell
adhesion molecule 6 in normal tissues
Cell adhesion molecules play a crucial role in a number of biological
functions, including homeostasis, embryogenesis, development of
neural tissue, inflammation, immune cell transmigration and immune
response.3 Moreover, expression of CEA and CEACAM6, but not
CEACAM1, inhibit colonocyte differentiation.41 CEA was also shown
to inhibit neurogenic and adipogenic differentiation.42 Altogether,
these results suggested that the differentiation block by CEA is pos-
sibly a result of clustering of multiple CEA molecules on the cell sur-
face and activation of downstream signaling cascades.35 In addition,
findings showed that opposite effects can be mediated by the 2
groups of CEACAM, as in cell differentiation. Hence, it is advanta-
geous for the tumor cells to overexpress CEACAM6 and to down-
regulate CEACAM1, so that they can escape apoptosis as well.43
4.2 | Physiological functions of carcinoembryonic
antigen/carcinoembryonic antigen-related cell
adhesion molecule 6 in cancer
The human CEACAM family genes are deregulated in many human
cancers. CEA is overexpressed in many gastrointestinal cancers,
including colorectal, esophageal, gastric, pancreatic, hepatocellular
and gallbladder carcinomas, breast cancer, lung cancer, the female
reproductive tract cancer (ovarian, cervical and endometrial carcino-
mas), medullary thyroid carcinomas, urinary bladder cancer and pros-
tate cancer.44 The question of the potential mechanism of CEA/
CEACAM6 effects arises. There are at least 3 key physiological pro-
cesses that function to maintain the homeostasis of a normal human
epithelium: cell proliferation, cell differentiation and apoptosis.45 The
disturbance of these processes, such as through an increase in cell
proliferation or inhibition of cell differentiation and apoptosis, or a
combination of these events, could contribute to malignant transfor-
mation of the epithelial cells. The forced overexpression of CEA/
CEACAM6 on the cell surface of several cell lines inhibited cell dif-
ferentiation without increasing the rate of cell proliferation.44 CEA/
CEACAM6 are mostly expressed on the apical surface of the human








F IGURE 2 Model of a CEA molecule. CEA has been named in
the CD system as CD66e. It consists of one IgV-like N-domain and
6 IgC-like domains (A and B). Glycosylation sites are shown as
lollipops. The glycophosphatidyl-inositol linkage to the cell
membrane is shown by an arrowhead
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normal pattern of expression is dramatically disrupted upon malig-
nant transformation when CEA and CEACAM6 are overexpressed
over the entire surface of the malignant cells whereas CEACAM1 is
largely absent.46 CEACAM6 are overexpressed in more than 50% of
all human adenocarcinomas. Based on these observations, the pre-
vailing hypothesis is that CEACAM6 overexpression plays an onco-
genic role.15 In contrast, transmembrane CEACAM1 was proposed
to be a tumor suppressor protein because it is downregulated in
many cancers and its forced expression in various cancer cell lines,
inc1uding prostate, colon and breast, decreases proliferation and
increases apoptosis.43 However, this generalization becomes blurred
based on the following observations: (i) detection of its overexpres-
sion in various cancers;47 (ii) its contribution to tumor aggressive-
ness;48 (iii) the nature of its immune suppressive effects;49 and (iv)
its pro-angiogenic properties.50
The GPI-anchored CEA/CEACAM6 have a variety of tumorigenic
effects on cells cultured in vitro and in xenograft mouse models.
Overexpression of CEA and CEACAM6 impedes myogenic, adi-
pogenic, neurogenic and colonic differentiation programs,41 inhibits
anoikis/apoptosis in colon and pancreatic cancer cells,51,52 disrupts
cell polarization and tissue architecture,41 increases chemoresis-
tance53 and enhances liver metastasis.52
Although earlier studies examined the role of CEACAM6 in gas-
trointestinal malignancies such as colon and pancreas, numerous
other carcinomas (e.g. breast, gastric, thyroid, B-ALL and multiple
myeloma) have been shown to overexpress CEACAM6, resulting in
increased metastatic potential.
The fundamental role of CEACAM 6 in breast cancer progression
will be discussed in detail below.
4.2.1 | Physiological functions of carcinoembryonic
antigen-related cell adhesion molecule 6 in breast
cancer
Carcinoembryonic antigen-related cell adhesion molecule 6 expres-
sion may represent an early event in the development of human
epithelial malignancies. Breast cancer cells illustrate CEACAM6 bet-
ter than normal breast tissue.54 As we have seen in precursor
lesions for both colorectal cancer and pancreatic ductal adenocarci-
noma (PDA), overexpression of CEACAM6 is predictive of progres-
sion to breast cancer.55 A retrospective analysis of 243 patient
samples revealed that CEACAM6 overexpression correlated with
tamoxifen resistance.56 In a multivariate analysis, CEACAM6 overex-
pression was an independent predictor of disease recurrence.57 Fur-
thermore, siRNA-mediated gene silencing of CEACAM6 in
tamoxifen-resistant MCF7 cell line derivatives reversed anchorage
independence and re-established endocrine sensitivity.57 Previous
work revealed that the development of resistance to tamoxifen in
breast tumor cells is related to augmented invasive potential58 as
well as CEACAM6 overexpression.54 The relationship between CEA-
CAM6 overexpression and acquired tamoxifen resistance leads to
invasion and migration in MCF-7.2A and MCF-7.5C breast cancer
cells.59 CEACAM6 is markedly overexpressed in estrogen-diminished
breast cancer cells. These in vitro data were further validated in
human breast cancer as CEACAM6 is recurrently overexpressed in
the setting of post-adjuvant endocrine therapy (e.g. tamoxifen). In a
cohort study of 840 invasive breast cancers and a separate valida-
tion cohort of 300 invasive breast cancers, CEACAM6 expression
was found to be present in 37.1% (312/840 patients) cases.26 Inter-
estingly, CEACAM6 expression was highest in HER2+ tumors (67%)
and lowest in triple negative breast cancer (25%).60 The patients in
this study were followed for a mean of 56.4 months, and 105 pa-
tients developed distant metastatic disease.26 Expression rates for
CEACAM6 were highest for patients with bone metastasis (42%).
The study reported that CEACAM6 adverse prognostic significance
for OS was independent of traditional prognostic factors (age,
tumor grade, size and Ki-67 expression level). One unique feature
of the signal transduction in HER2+ breast cancer cell lines and
CEACAM6 expression is the interaction of the HER2 pathway and
TGF-b signaling.17 Overexpression of CEACAM6 results in alteration
and reorganization of the ECM and activation of the TME playing a
key role in tumor invasion.54 CEACAM6 signaling increases SRC
activity, leading to increased IGF-I secretion, with autocrine and
paracrine stimulation of the IGF-1R activating the PI3K/AKT path-
way. Increased IGF-I expression results in MMP-2 elaboration, sub-
sequently altering the ECM and promoting a malignant TME.
Aggregation of CEACAM6 at the cell surface enhances anoikis
resistance through activation of SRC in a caveolin-1-dependent
manner, allowing for phosphorylation of its substrate focal adhesion
kinase.17
In addition, TGF-b signals through the TGF-b receptors acti-
vate alternate pathways, such as AKT/PI3K.17 CEACAM6 expres-
sion also serves as an indicator of response to therapy in Her2+
breast cancer. CEACAM6 underexpression indicated trastuzumab
responsive disease, whereas overexpression reflected trastuzumab-
resistant breast cancer.61 Further investigation is warranted to
identify whether CEACAM6 overexpression in metastatic breast
cancer patients also serves as a biomarker of response to gemc-
itabine, an approved third line therapy.61 CEACAM6 expression
would then serve as an avenue to identify high-risk cohorts of
breast cancer patients whose therapy could be specifically tailored
based on their underlying tumor biology, highlighting CEACAM6’s
role as both prognostic and underscoring its potential as a thera-
peutic target in epithelial carcinomas.
Based on the observations described above and the research
work ongoing in our research lab, we generated the following dual
hypothesis depicted in (Figure 3) below: (i) CEACAM6, beyond its
normal functions, including intercellular adhesion, cell death regula-
tion, and also its function as a general inhibitor of cell differentia-
tion, might play a novel role in malignant transformation and
tumor cell invasion/metastasis in breast cancer; and (ii) in addition
to a better understanding of the mechanisms that underpin CEA-
CAM6-mediated tumor cell invasion, our recent research findings
have the potential to validate CEACAM6 as a target to pave the
way towards the design of efficient therapeutic strategies against
breast cancer.
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4.2.2 | Physiological functions of carcinoembryonic
antigen-related cell adhesion molecule 6 in other
cancers
Over the past 2 decades, physiological and pathological roles of
this large gene family, mainly in cancer, infectious diseases,
immunology and diabetes, have been gradually elucidated in differ-
ent model systems.49 Although the growing knowledge on the
functions of CEACAM has already been beneficial to clinical prac-
tice and therapy, further understanding of their mechanism of
action in associated diseases and discovery of their participation
in other diseases may have greater impact on both clinical and
biological sciences in the future.
Carcinoembryonic antigen-related cell adhesion molecule 6 is
overexpressed primarily by colorectal, gastric and pancreatic can-
cers, with the vast majority of these tumors (>90%) expressing
CEA.62 In addition, it is expressed by the majority of medullary
thyroid cancers63 and more than 70% of non-small cell lung can-
cers.64 Reports of expression on many other cancers exist. Over-
expression of CEA colorectal cancer was described by inhibition
of terminal differentiation, loss of cellular polarization, distortion of
tissue architecture, and anoikis resistance,8 while in lung adenocar-
cinoma, it induces cell proliferation and anchorage-independent
growth.65,66 In gastric cancer, CEACAM6 promotes lymph node
metastasis, migration and invasion through increasing SRC phos-
phorylation.50 In contrast, in B-cell acute lymphoblastic lymphoma,
presumed enhancement of anoikis through increased caspase
activation as well as upregulation of the AKT cell survival path-
way.50 In addition, in multiple myeloma, CEACAM6 inactivation of
CTL (cytotoxic lymphocytes), through binding and cross-linking of
CEACAM6 on plasma cells, resulted in T-cell unresponsiveness
immune evasion.51,67 In addition, in pancreatic ductal adenocarci-
noma, increased metastatic potential through increased IGF-I
resulted in expression of proteolytic MMP-2 and MMP-9, altering
the ECM through SRC-AKT signaling pathway.68 These findings
correlate CEACAM6 overexpression with an increased metastatic
phenotype through elevated SRC activity and matrix metallopro-
teinase 2 (MMP2) expression. Hence, CEACAM6 overexpression
through activation of the SRC-AKT signaling provides chemoresis-
tance to gemcitabine in PDA cell lines.
5 | CONTRIBUTION OF
CARCINOEMBRYONIC ANTIGEN/
CARCINOEMBRYONIC ANTIGEN-RELATED
CELL ADHESION MOLECULE 6 IN CELL
SIGNALING
The CEA family plays an active role in multiple signal transduction
processes.69 Using transfected basophile leukemia cells as a model, it
has been demonstrated that GPI-bound CEA participates in a stimu-
latory signal transduction pathway.8
Many cell surface molecules, including receptors and adhesion
molecules, can convey information from the milieu to the interior
of the cells by means of signal transduction, so that the cells can
respond to the changes in the environment. The CEACAM gene
family of cell surface adhesion molecules is no exception. Never-
theless, Screaton et al35 suggested that the presence of CEA-spe-
cific GPI anchors, which reside in specific membrane microdomains
(lipid rafts), is essential for their cellular functions, at least as inhi-
bitors of cell differentiation. Screaton et al further suggested that
perturbation of integrin functions and integrin-ECM interactions
may be the underlying mechanism responsible for their inhibitory
effect on anoikis.35 When CEACAM6 is cross-linked in BxPC3
cells, anoikis resistance develops through activation of SRC in a
caveolin-1-dependant manner.53 SRC was identified as a key
player in tumor progression, providing oncogenic signals for mito-
genesis, cell survival, angiogenesis, invasion and metastasis.70
Caveolin-1 is an integral membrane protein found to co-precipitate
with SRC and is required for SRC kinases to activate integrin sig-
naling.71 The co-clustering of cell surface lipid raft-associated CEA-
CAM6 and integrin a5b1 leads to increased fibronectin binding to
the cells and recruitment of downstream signaling elements,
including ILK, Src family kinases, PBK and Akt/PKB.72 and, hence,
it has been proposed that clustering could activate the integrin
signaling pathway.11 A similar observation was made by another
group involving CEACAM6 and integrin a7b3 in pancreatic adeno-
carcinoma cell lines.53 Altogether, the GPI-anchored CEACAM can
mediate cell signaling through modulation of integrin functions
(Figure 4).
F IGURE 3 The novel predicted molecular mechanisms underlying
carcinoembryonic antigen-related cell adhesion molecule 6
(CEACAM6) promoting breast cancer progression
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6 | CARCINOEMBRYONIC ANTIGEN-
RELATED CELL ADHESION MOLECULE 6
TARGETED CANCER THERAPIES
Combinations of surgery, chemotherapy and radiation therapy repre-
sent the conventional treatment for cancer. However, with the
growing knowledge of cancer molecular biology, novel cancer thera-
pies are focused on personalized tumor targets to minimize systemic
toxicity and increase efficacy.73
In the present review, the role of CEACAM6 in various malignan-
cies has been discussed, as well as the identification of common and
unique pathways suspected to play a central role in the malignant
process. Furthermore, targeting CEACAM6 provides an opportunity
to treat several human malignancies, including the following potential
approaches.
6.1 | Anti-carcinoembryonic antigen-related cell
adhesion molecule 6 single chain variable fragment
therapeutic humanized
Mouse monoclonal antibody (Mab) 13-1, targeting a unique epitope
on human CEACAM6, leads to apoptosis of PDA cells expressing
CEACAM6 with an IC50 independent of antibody cytotoxicity.74 In
silico CDR grafting and antibody engineering generated single chain
variable fragment (scFv) humanized anti-CEACAM6 with a linker that
could be PEGylated to enhanced plasma half-life. The unique fea-
tures of humanized anti-CEACAM6 scFv include the ability to pro-
duce targeted tumor cell apoptosis and also represent an effective
combination with standard chemotherapy at very low doses.74
6.2 | Monoclonal antibodies
Utilizing GW-39 human colonic cancer cells, the effects of 3 Mabs
that target specific epitopes A1B1 domains (MN-15) and the NH2-
terminal (MN-3) present in CEACAM6, CEACAM5 and the A3B3
domain (MN-14) were investigated.15 Although treatment with MN-
15 and MN-3 resulted in an increase in survival, decreased adhesion
to the ECM and abrogated metastatic potential, these Mabs were
not efficacious with regard to tumor growth inhibition or regres-
sion.15 The availability of therapeutic monoclonal antibodies (uncon-
jugated and conjugated) targeting CEACAM6 provides potential
therapeutic opportunities likely to lead to a plethora of pre-clinical
and clinical activity in the next decade.
6.3 | Antibody-drug conjugates
A study of an antibody-drug conjugate targeting CEACAM6 investi-
gated the efficacy of the anti-CEACAM6-maytansinoid (DM1)
immune-conjugate in a murine xenograft model of PDA.75 The non-
conjugated Mab did not have anti-tumor activity, and showed rever-
sible and modest neutropenia. Further development of an antibody-
drug conjugate-based therapeutic approach in PDA has yet to be
pursued in early phase clinical trials.75
6.4 | Immunotoxin-based therapy
Targeting CEACAM6 in PDA using immunotherapeutic strategies has
been classified as direct or indirect.76 Indirectly using the Mab (114)
specific for CEACAM6 with no anti-tumor activity mediated cross-
linking of CEACAM6, which resulted in cytoplasmic accumulation
that increased efficacy of immunotherapy with saporin with caspase-
mediated apoptosis.76
6.5 | Knockdown mediated gene silencing
Knockdown models in CEACAM6-positive tumors identify key mech-
anistic pathways and potential targets involved in the development
of the malignant phenotype.77 Mice CEACAM6-specific siRNA
studies diminished tumor proliferation significantly, with a decreased
Ki-67 level impairing angiogenesis and increased apoptosis. Further-
more, CEACAM6-specific siRNA prevented metastasis and improved
survival without toxicity. Knockdown models inform us of the critical
role CEACAM6 plays in cancer development, further solidifying a
focus on this molecule as a therapeutic target.77
7 | SUMMARY AND PERSPECTIVE
The migration of cancerous cells from their primary location to dis-
tant sites is the cause of 90% of human cancer mortality.78 Dysregu-
lated overexpression of CEACAM6 plays a role in several of the
hallmarks of cancer, including uncontrolled proliferation, anoikis
resistance, neoangiogenesis, immune evasion, invasion and metasta-
sis. We believe that safely targeting CEACAM6 is most likely the
key to changing the natural history of the tumor and tumor microen-
vironment to allow novel combination therapies to be developed for
treating both solid and hematologic malignancies. We believe that
safely targeting CEACAM6 is most likely to change the natural
F IGURE 4 Carcinoembryonic antigen-related cell adhesion
molecule (CEACAM6) signaling pathways
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history of the tumor and TME and allow novel combination therapies
to be developed for treating both solid and hematologic malignan-
cies.
In conclusion, our review highlights the pathologic roles of CEA-
CAM6 in the development of multiple human malignancies, warrant-
ing an ongoing focus to successfully transition this cell adhesion
protein as a primary or adjunctive therapeutic target for anti-cancer
therapy in the clinic.
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